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Abstract
The use of extracorporeal membrane oxygenation (ECMO) has always been controversial 
in the past. Evidence was mainly build up in neonates and much controversy remained in 
adults. The main adult indications were mechanical support (e.g., in cardiogenic shock) 
or respiratory support (e.g., in the field of acute respiratory distress syndrome (ARDS)). 
Sepsis was historically often considered as a contraindication. As a consequence of sev-
eral worldwide flu outbreaks, the use of ECMO in infectious diseases increased. Besides 
in these viral infections, there was also growing interest for its use in bacterial septicemia, 
although often as escape therapy. In the recent years, other techniques gained increasing 
interest like for example, immunoadsorption, implemented in dialysis or ECMO circuits. 
In this chapter, we resume the available literature on the use of ECMO in septic shock 
including the use of immunoadsorption techniques.
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1. Introduction
Since the publication in the early 1970s of the first successful use of extracorporeal membrane 
oxygenation (ECMO) in a post-traumatic adult respiratory distress (ARDS) patient [1], ECMO 
has been used tremendously. The approach can be either by veno-venous cannulation, which 
is mainly used in hypoxic respiratory failure, or by veno-arterial cannulation, which is the 
preferred modality for cardiac (or combined) support. This implements that most indications 
are in the field of ARDS and cardiogenic shock states.
Septic shock is a serious disorder that, despite progress in treatment over the last decades, still 
has a high mortality (between 20 and 30%) [2]. The ECMO survival in septic neonates [3, 4] and 
children [5] has improved to ~90 and 75%, respectively. There is however far more controversy 
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on its use in adult refractory septic shock, although successful salvage cases have been pub-
lished [6, 7]. In parallel with the reports on its effectiveness during the influenza A (H1N1) 
outbreaks [8, 9], the interest for using ECMO in noninfluenza-induced sepsis has grown.
This chapter mainly focuses on indications, the difference between children and adults, caus-
ative pathogens, outcome and outcome prediction. It will not go into further detail on the 




A typical case of refractory septic shock is the following, unpublished, case out of our own 
ICU. A 42-year-old (type I) diabetic female was found unconscious by her husband and was 
brought to the emergency department after she was intubated at home by a medical team. 
She was diagnosed with diabetic ketoacidosis (initial pH 6.96) and was in of severe shock 
signs, requiring high doses of norepinephrine (0.5 μg/kg/’) in the emergency department. The 
patient was transferred to the ICU and after sampling (respiratory and hemocultures) empiri-
cal amoxicillin-clavulanate was started.
Because of refractory shock despite aggressive fluid resuscitation, vasopressin was added 
as well as low doses of hydrocortisone (3 × 100 mg daily). This led to normalization of 
blood pressures and pH, but the patient remained oliguric and overnight oxygenation dete-
riorated despite increasing PEEP and FiO2. Early continuous renal replacement therapy 
(CRRT) was started.
Approximately 14 h after ICU admission, she suffered cardiac arrest due to sudden onset 
of ventricular fibrillation. After initial successful resuscitation (after cardiac massage and 
defibrillation), her oxygenation and hemodynamic status deteriorated further, necessitating 
peripheral cannulation of the femoral vein and artery and afterward the initiation of veno-
arterial ECMO.
Antibiotic therapy was empirically switched to a combination of meropenem and vancomy-
cin and (single shot) amikacin. The initial hemocultures were positive for Gram-positive cocci, 
later identified as Enterococcus faecalis.
Over the following days, the patient suffered no further complications. Hemodynamics and 
oxygenation stabilized, inflammatory parameters slowly resolved. Seven days after starting 
mechanical support, ECMO support could be weaned and stopped.
Four days later, she suffered a new bacteremic episode with E. coli due to the development 
of empyema of the left hemithorax with. E. coli. This time, however, without the need for 
mechanical support. After thoracospic drainage and antibiotic switch to cefepime, based 
on culture results, inflammation went down. After repeat empyema, urokinase in loco was 
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administered with finally complete resolution of the empyema. The patient was extubated 
30 days after hospital admission after 6 weeks she was discharged to the ward.
2.1.2. ICU case series
The available literature on ECMO use in adult septic shock patients consists mainly of case 
reports or (usually single-centered) retrospective case series. In a recent multicenter study 
[10], the data from 42 Japanese intensive care units were retrospectively collected and propen-
sity score analysis was performed. Out of 3195 patients included in the JSEPTIC DIC study 
[11], 570 patients suffered from severe respiratory failure and in 285 of them respiratory fail-
ure was induced by lung infection. Overall 40 patients were supported with ECMO and these 
were matched with 150 patients in the control group. Sepsis-related organ failure (SOFA) 
scores were comparable (12 vs. 13).
A second propensity analysis was performed between the 25 ECMO patients with lung 
infection-induced respiratory failure and 89 patients in the control group. Overall no marked 
differences were found in 28-day mortality (47.2% in the control group vs. 32% in the ECMO 
group, p 0.168) and the in-hospital mortality (60.7% in control group vs. 40% in the ECMO 
group, p 0.07). However, in the second analysis comparing 89 controls with 25 ECMO patients 
with lung infection-induced respiratory failure, the survival time in the ECMO group was sig-
nificantly longer (hazard ratio (HR), 0.498; 95% confidence interval (CI), 0.279–0.889; p 0.018). 
The numbers of renal replacement therapy and vasopressor-free days were also significantly 
higher in the ECMO group.
These results are similar with those reported by Nesseler et al. [12], who questioned the use of 
ECMO in patients with intra-abdominal sepsis-induced ARDS. Although the overall ECMO 
group (n = 40) received more red blood cell transfusions, there was no significant difference 
in the rate of severe bleeding complications. The numbers of renal replacement therapy and 
vasopressor-free days were significantly higher in the ECMO group.
Another retrospective study [13] describes 32 ECMO patients with refractory septic shock. 
Fourteen patients had undergone cardiopulmonary resuscitation (CPR) in which ECMO was 
started during CPR (ECPR). The most frequently infected site was the lung and 20 patients 
had bacteremia. Thirteen patients (40.6%) were successfully weaned of ECMO but only seven 
(21.9%) survived to discharge. Interestingly, none of the patients in whom ECMO was initi-
ated more than 30 h after the onset of septic shock survived. CPR appeared to be an indepen-
dent predictor of in-hospital mortality (adjusted HR, 4.61; 95% CI, 1.55–13.69; p 0.006). On the 
other hand, patients with myocardial injury (higher peak troponin I > 15 ng/ml) had a lower 
risk of in-hospital mortality (adjusted HR, 0.34; 95% CI, 0.12–0.97; P = 0.04).
The low survival rate was partially due to the ECPR cases, of who only 2 out of 14 survived 
and they both had return of spontaneous circulation within minutes. One of the conclusions 
of this trial was evidently that ECMO should be avoided in patients who have received 
CPR. The fact that patients with signs of myocardial injury had better survival rates could 
be explained by the reversibility of septic cardiomyopathy. There are two patterns of early 
death in septic shock: distributive shock or a cardiogenic form of septic shock [14]. ECMO 
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may be a valuable support in patients with the latter form that is unresponsive to highly 
dosed cathecholamines [15]. Finally, survivors appeared to have lower SOFA score at day 3 
compared with the nonsurvivors (15 vs. 18, p = 0.01).
In another case series [16], 14 patients received ECMO support as salvage therapy for refrac-
tory septic shock, 24 h (3–108) after shock onset. Mean simplified acute physiology score 
(SAPS) III was 84 (75–106) SOFA score was 18 (8–21). Twelve patients (86%) could be weaned 
off and 10 patients (71%) were discharged home and were alive after a median follow-up of 
13 months (3–43) with normalized ejection fraction and a good quality of life.
During a 6-year period, 52 septic shock patients had undergone ECMO support in a South 
Korean ICU [17]. Almost half of them (n = 21) was receiving CPR at the time of ECMO implan-
tation. Not surprisingly overall outcome data were poor with only 15% survival to discharge. 
The nonsurvivors were significantly older than survivors (59.3 vs. 43.8 years, P = 0.009) and 
all patients aged 60 or older died.
2.1.3. Specific populations
2.1.3.1. Obstetrical cases
Maternal sepsis is a predominant cause of maternal death in low-income countries, but also in 
Western countries maternal mortality from sepsis has increased [18]. In 15 years, the incidence 
in the UK almost doubled from 0.65 to 1.12 per 100,000 cases [19]. Twenty-one deliveries per 
100,000 develop sepsis with a case fatality rate of 7–8%. In the presence of septic shock, mor-
tality goes up to 60%. Pregnant women are not only vulnerable to sepsis because of changes 
in the immune system, predisposition to pyelonephritis due to ureteral compression and 
increased invasive interventions. They also tend to decompensate quickly in case of sepsis 
due to the physiological changes (cardiovascular, respiratory, and metabolic) of pregnancy. 
These changes can finally also mask the early recognition of sepsis.
Sharma et al. [20] examined 31 published reports (with a total of 67 patients) of ECMO use 
in pregnancy. Fetal survival was 70% and maternal survival 80% which was comparable to 
nonpregnant patients requiring ECMO support. Fifteen reports of V-V ECMO, 16 reports 
of V-A ECMO, and 1 report of a lung assist device. But, indications for ECLS use included 
mainly severe ARDS, postpartum cardiogenic shock and amniotic fluid embolism. Besides a 
lot of H1N1 infected patients, only one patient with staphylococcal-induced ARDS and septic 
shock was included. There was no consensus on an optimal anticoagulation strategy in these 
patients, though most preferred to keep anticoagulation at lower therapeutic levels. A few 
cases of vaginal bleeding were reported, but occurrence of catastrophic bleeding was rare.
After this review, several case reports on bacterial septic shock were published [21, 22]. A 
24-year-old multiparous woman was admitted with multiple organ failure in the third tri-
mester of pregnancy [21], after suffering from high fever and diarrhea since 1 day. Cesarean 
section was performed due to fetal distress but the patient remained in refractory circulatory 
failure with consequent, progressive multiple organ failure. Cateacholamines were increased 
after ICU admission and low doses hydrocortisone were given.
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Continuous hemodiafiltration was initiated 4 h after ICU admission. Piperacillin/tazobac-
tam was started at hospital admission but after the identification of Streptococcus pyogenes, 
the diagnosis of Streptococcal toxic shock syndrome was made. Antibiotics were switched 
to penicillin, and clindamycin and intravenous immunoglobulins were added. Despite the 
abovementioned therapy and the increase of the hemofilter membrane area, multiple organ 
failure continued to progress. Repeated echocardiography showed left ventricular ejection 
fraction (LVEF) of 10%. Therefore, veno-arterial ECMO was initiated from the right atrium 
to the right femoral artery. With blood and oxygen flows of both 3.0 L/min lactate levels 
decreased from 20 to 8.9 mmol/l after 24 h of ECMO support. On day 7, she was weaned 
from ECMO; on day 8, vasopressors were stopped; on day 10, ventilation could be stopped 
and renal function recovered. The patient was discharged after 53 days and cardiac function 
recovered after 4 months. The patient suffered no bleeding complications.
In a very recent case report [22], another 24-year-old was readmitted to the hospital 2 days 
after a normal vaginal delivery following an uneventful pregnancy. Despite starting vaso-
pressors and broad-spectrum antibiotics, she continued to decline with intubation 14 h after 
admission. An echocardiogram revealed an LVEF of 20%. Blood cultures grew Gram-positive 
cocci (group a streptococcus). The patient was transferred to a tertiary center where the diag-
nosis of endometritis was made and emergent total abdominal hysterectomy was performed 
after starting VA ECMO support. The fascia was left open and wound vacuum system was left 
in place. Vasopressors could be weaned on postoperative day (POD) 1, but she returned to the 
operating room (OR) for intra-abdominal bleeding. Afterward she suffered no more adverse 
events until decannulation, which was done on POD 5 in the OR. She was extubated on POD 
7 and by POD 12 LVEF had normalized.
Finally, a third case of an 18-year-old nulliparous woman was reported [23]. She was admitted 
after 26 weeks of pregnancy with high fever, nausea, headache and increasing inflammatory 
parameters. After blood cultures were taken, empirical cefuroxime (750 mg every hours intra-
venously). On the second day of hospitalization, contractions started and a preterm low birth 
weight premature girl was born after urgent C-section. Surgery was uncomplicated but sud-
denly tachycardia developed and diffuse intravascular coagulation (DIC) with consecutive 
bleeding problems from wounds and catheter insertion sites started after about an hour after 
the procedure. Sepsis was supposed to be the cause of the DIC and antibiotics were switched 
to vancomycin and meropenem after new hemocultures were obtained. The patient was trans-
ferred to the ICU because of pulmonary edema, which started 4 h after the bleeding problems.
She was intubated and vasopressors were started. Blood cultures grew positive for Staphylococcus 
aureus and Enterobacter cloacae. As septic shock and cardiorespiratory failure deteriorated, hys-
terectomy was performed 4 days after the C-section. Afterward the patient recovered slightly, 
but respiratory failure further deteriorated and 3 days after the hysterectomy VA ECMO was 
started between the femoral vein and subclavian artery. She suffered from a hematoma at the 
arterial insertion point which encapsulated and infected, resulting in a thoracotomy. This had 
to be repeated several times because of bleeding complications, but finally the ECMO could be 
weaned 3 weeks after it had been initiated. Respiratory failure regressed and in the end she was 
discharged home after 105 days.
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2.1.3.2. The immunocompromised patient
Several publications [24–27] report on the use of ECMO in immunocompromised patients, 
mainly kidney and liver transplanted patients. Infections are the leading cause of critical ill-
ness and mortality in liver transplant patients. More than half of the patients develop an infec-
tion during the first year, almost always ending in ICU admission. Bacteremia associated from 
10 to 52%. Mortality is higher in recipients with bacteremia due to ‘ESKAPE’ pathogens, which 
stands for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter species [28]. Over a 7-year period, a South 
Korean university center [24] used ECMO in 8 (of in total 854) liver transplanted patients with 
refractory septic shock. Primary liver disease in these patients was hepatocellular carcinoma 
(n = 3), liver cirrhosis due to hepatitis B infection (n = 3), alcoholic liver cirrhosis (n = 1) and 
toxic hepatitis (n = 1). These patients suffered mainly from intra-abdominal and lung infec-
tions. They were infected by a variety of pathogens, but in five out of eight, Acinetobacter 
baumannii was cultured.
ECMO was initiated after a median of 6, 5 h under vasoactive drugs were started and six 
patients received cardiopulmonary resuscitation (CPR) with initiation of ECMO after a 
median of 41, 5 min (range, 20–154 min) after onset of CPR. The interval between the trans-
plantation and the onset of infection was not mentioned. Three patients (37.5%) were success-
fully weaned from ECMO but only 2 (25%) survived until hospital discharge. Illness severity 
scores at onset were not different between survivors and nonsurvivors. Lactate levels and 
SOFA scores tended to decrease over the course of treatment in survivors while in nonsurvi-
vors total bilirubin and CRP levels tended to increase.
Another successful use of ECMO support was reported in a 49-year-old male liver trans-
plant [25] suffering from alcoholic liver cirrhosis-induced acute-on-chronic liver failure. 
Immediately before the emergent liver transplantation, he developed pulmonary tuberculosis 
and tuberculosis peritonitis. The latter caused intermittent small-bowel obstruction and sub-
sequent ischemia and led to emergency adhesiolysis on POD 114. In the postoperative phase, 
the patient developed aspiration pneumonia leading to septic shock and ARDS. After 11 days 
of ECMO support, the patient could be weaned and finally was discharged on day 204.
The largest available series of ECMO in adult liver transplant patients was published by 
Park et al. [26]. Over a 3-year period, 18 out of 1076 liver transplanted patients required VV 
ECMO. The main indication, however, was refractory respiratory failure, not necessarily with 
concomitant septic shock. Eight patients could be weaned.
The electronic medical records of kidney transplanted (KT) patients that received ECMO 
support were reviewed [27]. Between December 2010 and December 2014, 12 KT patients 
required ECMO management. In half of them, this was due to bacterial sepsis only or com-
bined viral/bacterial pneumonia or sepsis. The others suffered from viral pneumonia or in 1 
case fulminant myocarditis secondary to fungemia. The mean period between the KT and the 
ECMO support was 44.4 months (range, 1.2–184.3 months) and in three patients ECMO was 
started during the admission for the transplant.
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The mean duration of ECMO support was 9.1 days (range, 3.5–15.1 days) and six patients 
were successfully weaned from ECMO. However, two of them died after being weaned 
from ECMO. During ECMO support, all patients needed renal replacement therapy (RRT). 
Among the six survivors, five could be weaned after a mean period of 53 + 37.5 days (range, 
16–97 days). The pH just before the beginning of ECMO appeared to be significantly lower in 
the nonsurvivors than in the survivors (P = 0.046).
2.2. Children
In contrast with the adult population, there is far more acceptance for using ECMO in 
pediatric cases of septic shock. In a French study [29], the use of VA ECMO in 14 neonates 
and 9 children with refractory septic shock was reported. The mean age of the pediatric 
population was 30 months. Overall, in more than half of the cases septic shock was due 
to streptococcal or E. coli bacteremia. Fifty-seven percent of the neonates suffered from 
Streptococcus B infection. All patients were ventilated and received vasopressors before 
ECMO initiation.
In two patients, cannulation was performed during chest compressions because of cardiac 
arrest. The mean duration of support was 7.43 days (range, 1–17) and 5.9 days (range, 3–10) in 
neonates and children, respectively. Six neonates (42%) and three children (37%) had mechan-
ical (mainly clotting) complications with the ECMO circuit. One neonate and three children 
required renal replacement therapy.
The overall survival rate was 59.1%, with 64.% of the newborns (n = 9) surviving to discharge 
and 50% (n = 4) of the pediatric population. So survival was significantly higher in the new-
borns (p = 0.02), although ECMO weaning rates were comparable (64 and 66% respectively).
These results are somewhat lower than those reported in older trials [3, 4, 30, 31], with sur-
vival rates up to 80% in neonates and 74% in older children. But in the French cohort [29], the 
patients seemed to have more severe cardiovascular failure with higher inotropic scores and 
lower pH. The authors conclude that ECMO can be safely used to resuscitate children with 
refractory shock and propose to transfer infants to an ECMO referral center in case of persist-
ing oliguria and without decrease of lactate levels within 6 h after the initiation of maximum 
drug therapy.
In some of the older trials [5], central cannulated ECMO (atrio-aortal cannulaton) was used 
in 23 children, almost all (96%) having at least three organ failures and eight (35%) suffered 
cardiac arrest and required massage during ECMO placement. All had microbiological evi-
dence of infection and meningococcemia was the most common causative pathogen. Despite 
the severe setting at onset, 18 patients (78%) could be weaned of ECMO and 17 (74%) survived 
to hospital discharge.
More recently, several case reports of pediatric ECMO use were published in specific indica-
tions [32] like liver transplanted infants or with more rare pathogens [33] like community-
acquired Legionella infection.
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Finally, a Taiwanese group [34] recently published their retrospective single center review 
of 55 pediatric septic shock patients. In this cohort, overall survival to discharge was 31%. 
However, 25 patients were immunocompromised, in whom mortality was 75%. Mean ECMO 
duration was 9 days (range, 0–103) with a duration in survivors that doubled the one in non-
survivors (14 vs. 7 days, p = 0.09). In 17 of them, causal pathogens could be identified of which 
7 were bacterial and 1 was an invasive fungal infection. In the previously healthy kids, in 18 
cases with an identified pathogen 10 were bacteremic (mainly pneumococcal).
3. Adjunctive therapies
The mainstay of etiological treatment in septic shock remains source control and the adminis-
tration of anti-infective agents. Especially with regard to the latter, dosing issues are extremely 
important. Finally, there is also some emerging literature, unfortunately mainly anecdotal, on 
the use of immunoadsorptive strategies.
3.1. Source control
Resection or drainage of an infectious inoculum is important. Due the necessity of anticoagu-
lating ECMO treated patients, this is not without risk of bleeding during or after (at restart of 
anticoagulation) the procedure. However, as mentioned in previous sections of this chapter, 
performing surgical procedures in ECMO patients is feasible [22, 23].
3.2. Dosing of anti-infective agents
In the last decade, the interest in pharmacodynamics and therapeutic drug monitoring (espe-
cially for antibiotics) has grown tremendously. With regard to prescribing antibiotics, several 
reports have dealt with therapeutic drug monitoring in ICU patients in the absence [35] or in 
the presence [36] of concomitant use of renal replacement therapy.
However, there are no clear guidelines for dosing antibiotics in ECMO-treated patients. 
Therefore, the interest on the matter increased in the latest years and several publications 
investigated this topic [37–39], mainly in the class of beta-lactam antibiotics.
In ECMO patients, the volume of distribution increases tremendously, but clearance is 
usually lower than controls [37]. Although pharmacokinetic variability is high, decreased 
meropenem clearance usually compensates for ECMO and critical illness-related increases 
in the volume of distribution. With standard 1 g IV dosing 8-hourly, target concentrations 
of >2 mg/L are usually met, but an increase in dose may be appropriate in patients with 
elevated creatinine clearance or when higher concentrations are needed for less susceptible 
microorganisms.
The use of continuous infusions of carbapenems might be useful in this regard [38]. In a 
pediatric ECMO case, a bolus of 40 mg/kg meropenem followed by a continuous infusion of 
200 mg/kg/day resulted in target attainment of 100% for serum and lung concentrations above 
the MIC.
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Also, other beta-lactam antibiotics [39] were investigated. For piperacillin/tazobactam insuf-
ficient concentrations were more frequent than with meropenem therapy in the treatment of 
Pseudomonas aeruginosa infections.
Also while prescribing antifungal agents, caution is warranted for subtherapeutic exposure. 
In pediatric ECMO case [40], insufficient plasma levels were measured despite the adminis-
tration of normal to high doses of caspofungin.
3.3. Immunoadsorption
In the last decade, several publications report on the use of cytokine adsorption techniques 
[41–46]. In several case reports [41–43], the Cytosorb hemoadsorption column (Linc Medical, 
Leicestershire, United Kingdom) was installed either in the ECMO circuit or in the CRRT 
circuit in order to stabilize septic shock patients more rapidly and to improve their outcome. 
Cytosorb removes the proinflammatory cytokines and has been shown to reduce vasopressor 
doses and serum inflammatory markers in septic patients. A similar device is the polymethyl-
methacrylate membrane hemofilter is also available for clinical use and a report on its use has 
been published [46]. Although promising, the addition of these immunabsorption techniques 
is costly and still under investigation.
4. Outcome prediction
Giving the debatable indication (at least in adults), the high cost and the invasive nature of 
ECMO treatment and the consequent complications, outcome prediction before treatment 
initiation is important. In Table 1, the outcome predictors of the previously cited publications 
Table 1. Outcome predictors for ECMO use in septic shock.
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are listed and a few other publications [47–49], that have investigated survival predictors for 
septic shock patients under mechanical support, were added.
In a Korean case series [47], 28 patients were treated with ECMO, of whom 21 with VA 
ECMO. The overall survival to discharge rate was 35.7% and predictors of survival appeared 
to be: a simplified acute physiology score II (SAP II) of 80 or less and pre-ECMO albumin levels.
In another report [48], better outcomes were seen if door-to ECMO times were < 96 h. 
Furthermore, survival was better in case of Gram-positive infections rather than Gram-negative 
septic shock. Finally, outcome was better for pneumonia rather than primary bloodstream 
infections.
The same group [49] also published that the implementation of ECMO during CPR is not 
beneficial for septic shock patients.
5. Conclusions
Although the use of VA ECMO has been controversial in adults with septic shock, it is com-
monly used in the pediatric population, with good results. Despite the ongoing controversy, 
VA ECMO has seen increased use in septic adults with SICM, with survival and complete 
cardiac recovery in as high as 70% of patients. However, outcomes vary enormously and VA 
ECMO seems especially beneficial in certain subsets, like, for example, lung infection-induced 
septic shock. On the other hand, survival rates are poor when ECMO is initiated in a CPR 
setting. Other currently reported, negative predictors (at ECMO onset) are SAPS II scores >80, 
Gram-negative septicemia, age > 60 years, SOFA scores >15. Also in immunocompromised 
patients, mortality rates are high and ECMO, which does not exclude its use in escape therapy 
(e.g., after liver transplantation). The use of ECMO does not prohibit other surgical interven-
tions, with the aim of infectious source control. Procedures like hysterectomy, laparotomy, all 
have been performed under or immediately before ECMO therapy.
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